Get the Stockscreener App
0.4235
2.19%
-0.0106
Gossamer Bio Inc stock is traded at $0.4235, with a volume of 1.36M.
It is down -2.19% in the last 24 hours and down -79.88% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$0.4341
Open:
$0.4243
24h Volume:
1.36M
Relative Volume:
0.10
Market Cap:
$98.11M
Revenue:
$44.05M
Net Income/Loss:
$-156.16M
P/E Ratio:
-0.6163
EPS:
-0.6872
Net Cash Flow:
$-158.51M
1W Performance:
-7.70%
1M Performance:
-79.88%
6M Performance:
-86.08%
1Y Performance:
-68.78%
1-Day Range:
$0.405
$0.4342
1-Week Range:
$0.405
$0.4851
52-Week Range:
$0.3312
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.4239 | 100.48M | 44.05M | -156.16M | -158.51M | -0.6872 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.64 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.21 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.13 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.94 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.26 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Uncertainty After Phase 3 Setback and Widening Los - AD HOC NEWS
[EFFECT] Gossamer Bio, Inc. SEC Filing - Stock Titan
Calif. biotech company lays off almost half of staff after 78% stock drop - SFGATE
Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart
Gossamer Bio, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Gossamer Bio (NASDAQ:GOSS) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Investor Lawsuit After Phase 3 Trial Failure and E - AD HOC NEWS
Gossamer Bio (GOSS) reports Q4 loss, beats revenue estimates - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, ... - Bluefield Daily Telegraph
Gossamer Bio earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Gossamer Bio Q4 2025 Earnings: Revenue Beats Forecasts, Loss WidensNews and Statistics - IndexBox
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
GOSS Exceeds Q4 Revenue Expectations Amid PROSERA Results Analys - GuruFocus
Gossamer Bio Inc. announced that, during the evaluation of the impact of the Prosera trial results on its clinical programs, it has suspended new patient enrollment in the Phase III Seranata study for patients with progressive fibrosing interstitial lung disease (Ph - Bitget
Gossamer Bio: Fourth Quarter Financial Results Overview - Bitget
Gossamer Bio Q4 net loss widens - TradingView
Gossamer Bio (NASDAQ: GOSS) registers up to $200M shelf for equity, debt - Stock Titan
Gossamer Bio: Q4 Earnings Snapshot - Barchart
Gossamer Bio 2025 10-K: Revenue $48.5M, Net loss $170.4M - TradingView
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
[10-K] Gossamer Bio, Inc. Files Annual Report | GOSS SEC FilingForm 10-K - Stock Titan
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Gossamer Bio (NASDAQ: GOSS) registers $200M shelf for multiple securities - Stock Titan
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Business Wire
Analysts Adjust Ratings and Targets for Gossamer Bio - National Today
Gossamer Bio, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Investor Scrutiny After Sharp February Plunge - AD HOC NEWS
GOSS Stock Quote Price and Forecast - CNN
Gossamer Bio options imply 46.1% move in share price post-earnings - Yahoo Finance
Gossamer Bio Inc Stock (ISIN: US38198T1034) Surges on Clinical Momentum and Analyst Optimism - AD HOC NEWS
GOSS News Today | Why did Gossamer Bio stock go up today? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Shareholders to Reach Out - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - PR Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
GOSS Stock Price, Quote & Chart | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GOSS Gossamer Bio NASDAQ $0.56 10 Mar 2026: Pre-market ahead of Mar 12 earnings - Meyka
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
Can Gossamer Bio Inc withstand a market correction2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Gossamer Bio Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - ACCESS Newswire
GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts remain bullish on Gossamer Bio (GOSS) citing undervaluation - MSN
683 Capital Management, LLC Increases Stake in Gossamer Bio Inc - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HC Wainwright Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $5.00 - MarketBeat
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):